February 28, 2022Breda, the Netherlands – argenx , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that. | February 28, 2022
28.02.2022 - February 28, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate .
Initiated global VYVGART (efgartigimod alfa-fcab) commercial launch Expect data from five registrational trials of efgartigimod by first quarter of 2023 Announcing four new efgartigimod indications